New study shows triple inhaler helps COPD patients breathe easier
NCT ID NCT05535972
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study looked at how well the triple-combination inhaler Trelegy Ellipta works for people with chronic obstructive pulmonary disease (COPD) in real-world settings. Over 12 weeks, 463 adults aged 40 and older with moderate-to-severe symptoms used the inhaler once daily. Researchers measured changes in health status, shortness of breath, and lung function to see if the treatment improved daily life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY DISEASE, CHRONIC OBSTRUCTIVE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Dongguan, 523326, China
Conditions
Explore the condition pages connected to this study.